Abstract. Many studies have revealed that S100A4 is involved in cancer progression by affecting a variety of biological functions. Our previous study showed that S100A4 influences many biological properties of gastric cancer cells; however, the underlying mechanisms are far from clear. In this study, we used cDNA microarray analysis to investigate the global alterations in gene expression in MGC803 gastric cancer cells after siRNA-mediated S100A4 inhibition. Among the total genes investigated, 179 differentially expressed genes (38 upregulated and 141 downregulated) were detected in S100A4-siRNA transfected MGC803 cells compared with NC-siRNA transfected cells. We focused on the GDF15 gene, which was significantly downregulated after S100A4 inhibition. ChIP studies showed that the S100A4 protein binds to the GDF15 promoter, implicating S100A4 in GDF15 regulation at the transcriptional level. GDF15 overexpression promoted CSC-like properties of MGC803 cells, such as spheroid and soft-agar colony forming abilities. S100A4 inhibition suppressed the CSC-like properties of the cells, whereas, GV141-GDF15 vector transfection reversed these effects. Our results suggest that S100A4 influences the CSC-like properties of MGC803 gastric cancer cells by regulating GDF15 expression.
Introduction S100A4 (also known as calvasculin), belongs to the S100 family of Ca 2+ -binding proteins. The human S100A4 gene is located in chromosome 1q21. The S100A4 protein occurs as noncovalently bound homodimers with the ability to interact with an array of target proteins in a calcium-dependent manner (1) . S100A4 overexpression has been reported in several types of cancer and is associated with invasion and metastasis and poor patient prognosis (2) (3) (4) . Many studies have confirmed that S100A4 is involved in a variety of biological effects. Knockdown of S100A4 inhibited the invasiveness of esophageal squamous cell carcinoma cells, with elevated E-cadherin expression (5) . The siRNA-mediated silencing of S100A4 downregulated MMP-13 expression and suppressed breast cancer cell migration and angiogenesis (6) . Recently, increased expression of P27 and cleaved caspase-3 has been reported in S100A4-deficient pancreatic tumors, while cyclin E expression was found to be decreased. S100A4-deficient tumors have reduced expression of vascular endothelial growth factor (VEGF), suggesting reduced angiogenesis (7) . Our group previously showed that S100A4 inhibition mediated by RNA interference (RNAi) led to reduced proliferation and increased apoptosis of BGC823 gastric cancer cells. Intratumoral injection of pS100A4-shRNA suppressed tumor growth in nude mice. We also found that S100A4 inhibition decreased expression of both NF-κB p65 and phosphorylated (Ser32)-I-κB-α in BGC823 cells (8) . These studies indicate that S100A4 exerts its function by affecting downstream gene expression although the mechanisms remain to be fully clarified.
Accumulating evidence suggests that cancer-initiating cells (CIC) or cancer stem cells (CSC) are a rare subpopulation of cells with self-renewal capacity (9, 10) and are responsible for cancer initiation, progression, metastasis, relapse, radioresistance and chemoresistance (11) (12) (13) . S100A4 knockdown in head and neck CICs reduced their stemness properties both in vitro and in vivo (14) . Our previous study showed that S100A4 mediated the effects of IL-1β on the CSC-like properties of MGC803 gastric cancer cells (unpublished data); however, the mechanisms underlying this effect are far from clear. In this study, we investigated the hypothesis that S100A4 affects the CSC-like properties of MGC803 gastric cancer cells via regulation of downstream gene expression.
In this study, cDNA microarray analysis showed differential expression of 179 of the total genes after siRNA-mediated S100A4 knockdown in MGC803 gastric cancer cells. We then focused specifically on the GDF15 gene, which was significantly downregulated after S100A4 inhibition. ChIP assays showed that S100A4 protein binds to the GDF15 promoter, indicating that S100A4 may participate in the transcriptional Transfection of S100A4-specific small interfering RNA (siRNA). Duplex siRNA oligos specific for human S100A4 were synthesized by GenePharma (Shanghai, China). The siRNA sequences were as follows: 5'-GCAUCGCCAUGAUGUGUA ATT-3' , and 5'-UUACACAUCAUGGCGAUGCTT-3'. Negative control (NC) siRNAs were provided by GenePharma. MGC803 cells were transfected with 20 nM of siRNA using Lipofectamine™ 2000 transfection reagent (Invitrogen) according to the manufacturer's instuctions. The cells transfected with S100A4-siRNA or NC-siRNA were referred to as MGC803/S100A4-siRNA cells or MGC803/NC-siRNA cells, respectively. Cells were harvested at 48 h after transfection for use in the subsequent associated experiments.
RNA extraction and quantitative reverse transcription polymerase chain reaction (qRT-PCR).
Total cellular RNA was extracted using TRIzol reagent (Invitrogen). Reverse transcription reaction was performed using the First-Strand cDNA synthesis kit (Promega, Madison, WI, USA) with 1 µg of RNA in a final volume of 20 µl. The newly synthesized cDNA was amplified by quantitative PCR and PCR analysis was carried out using SYBR Premix Ex TaqII (Takara Biotechnology, Tokyo, Japan). Reactions were processed and analyzed on an ABI 7500 Real-time PCR system (Applied Biosystems, Carlsbad, CA, USA). The PCR conditions were 30 sec at 95˚C followed by 45 cycles of 95˚C for 5 sec and 60˚C for 34 sec. All of the quantitative PCR reactions were run in triplicate, and data were analyzed according to the comparative Ct (2 -∆∆Ct ) method. The qPCR primers (Table I) were synthesized by Sangon Biotech (Shanghai, China). Experiments were carried out independently three times.
Western blot analysis. Whole cell extracts were prepared by homogenizing cells in a lysis buffer [50 mM Tris (ph 7.2), 500 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 10 mM MgCl 2 with 10 µg/ml leupeptin, 10 µg/ml aprotinin, and 1 mM PMSF]. Protein lysates were quantified by the Bradford method. Proteins were separated by sodiumdodecyl sulfate polyacrylamide gel (12%) electrophoresis, transferred onto PVDF membranes (Millipore, Bedford, MA, USA) and blocked with TBST supplemented with 5% non-fat milk. The membranes were immunoblotted with primary antibodies: rabbit anti-S100A4 antibody (1:500 dilution; Abcam); rabbit anti-GDF15 antibody (1:1,000 dilution; ImmunoWay); and rabbit anti-β-actin antibody (1:500 dilution; Santa Cruz). After washing, membranes were incubated with a peroxidase-conjugated second antibody: mouse anti-rabbit IgG for S100A4 or GDF15 and β-actin. Immunoreactivity was detected using an enhanced chemiluminescence reagent (Amersham Biosciences, Freiburg, Germany) and visualized with Micro Chemi (DNR Bio-Imaging Systems, Jerusalem, Israel). Experiments were carried out independently three times.
Microarray analysis. Total RNA from the MGC803/ S100A4-siRNA cells or MGC803/NC-siRNA cells was extracted, cleaned up, reverse-transcribed, and hybridized to the Genechip ® PrimeView TM human Gene Expression array (Affymetrix, Santa Clara, CA, USA) by the GeneChem Co. (Shanghai, China). Fold changes in expression and P-values were calculated from the raw data. Genes showing significant differential expression were defined as those exhibiting changes in expression exceeding 1.5-fold with a P-value of <0.05; the differentially expressed gene transcripts were then included in further analyses. Briefly, gene transcripts showing significant changes in expression in the transcriptome array analysis were mapped to their corresponding Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and Gene Ontology (GO) molecular functions.
Chromatin immunoprecipitation (ChIP) assay. ChIP assays were performed using ChIP-IT ® Express Enzymatic kits (Active Motif) according to the manufacturer's instructions. Briefly, ~4.5x10 7 MGC803 cells were cross-linked with 60 ml 1% formaldehyde for 10 min at 37˚C. The cells were then resuspended in 3 ml lysis buffer containing 15 µl PIC and 15 µl PMSF and incubated for 45 min on ice. Fragments (150-450 bp) were generated by enzymatic shearing. The recovered supernatant (400 µl) was incubated with 10 µg anti-S100A4 antibody (Abcam) or 10 µg normal isotype control IgG and 25 µl magnetic beads overnight at 4˚C with rotation. Approximately 200 µl of the recovered supernatant was used as the input. After washing the magnetic beads/antibody/DNA complex, crosslinking was reversed by incubation with 10 µl 5 M NaCl at 65˚C for 8 h. The DNA samples were then purified and analyzed by quantitative polymerase chain reaction (qPCR) using the primers listed in Table I . Experiments were carried out independently three times.
Construction and transfection of the GDF15 expression vector.
GV141-GDF15, the expression vector specific for human GDF15 was constructed by GeneChem. GV141-empty (negative control) was provided by GeneChem. MGC803 cells were transfected with these vectors using Lipofectamine™ 2000 transfection reagent (Invitrogen) according to the manufacturer's instructions. The cells transfected with GV141-GDF15 or GV141-empty were referred to as MGC803/GV141-GDF15 cells or MGC803/ GV141-empty cells, respectively. Cells were harvested at 48 h after transfection for the associated experiments.
Spheroid formation assay. Single cell suspensions of transfected MGC803 cells were plated (1x10 3 cells/well) in 24-well Ultra-Low Attachment Plates (Corning) and maintained in serum-free DMEM/F-12 medium supplemented with 20 ng/ml basic fibroblast growth factor, 20 ng/ml epidermal growth factor, 10 mmol/l hEPES, 0.4% bovine serum albumin and B27 supplement (1:50 dilution; Invitrogen) for 7 days. The number of spheroids (diameter >75 µm) was counted and representative images were captured under an inverted microscope (Olympus, Tokyo, Japan). Experiments were carried out independently three times.
Soft-agar colony formation assay. Single cell suspensions of transfected MGC803 cells were plated into 6-well plates (3x10 3 cells/well) in RPMI-1640 (Invitrogen) containing 10% FBS and 0.3% low melting-point agarose (Amresco, Solon, Oh, USA) on a base layer of 0.5% low melting-point agarose. After incubation for 7 days at 37˚C, the number of colonies >50 µm was counted and photographed. Experiments were carried out independently three times.
Rescue assay after co-transfection of S100A4-siRNA and GV141-GDF15. S100A4-siRNA and the GV141-GDF15 vector were co-transfected into MGC803 cells using Lipofectamine™ 2000 (Invitrogen) to generate MGC803/S100A4-siRNA+ GV141-GDF15 cells. S100A4-siRNA and GV141-empty vector were co-transfected to generate MGC803/S100A4-siRNA+ GV141-empty cells as a control. At 48 h after transfection, cells were harvested for investigation of CSC-like properties by spheroid formation assays and soft-agar colony formation assays. Experiments were carried out independently three times.
Statistical analysis. Statistical analysis was carried out by Student's t-test using the Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL, USA), where P<0.05 was considered to indicate statistical significance.
Results

Knockdown of S100A4 expression in MGC803 cells by RNA interference (RNAi).
The effect of S100A4-siRNA transfection on S100A4 gene silencing was evaluated by both qRT-PCR and western blot analyses. As shown in Fig. 1 , endogenous S100A4 mRNA and protein levels were reduced in MGC803/ S100A4-siRNA cells at 48 h post-transfection compared with those in MGC803/NC-siRNA cells. There was no significant difference in β-actin expression between the two groups. These data indicate that S100A4-siRNA effectively suppressed S100A4 expression in MGC803 cells.
Gene expression profiling in MGC803 cells after S100A4 silencing. Alterations in the expression of the MGC803 cell transcriptome associated with S100A4 knockdown were analyzed by cDNA microarray profiling. Compared with the profile of MGC803/NC-siRNA cells, differential expression of 179 transcripts was identified in MGC803/S100A4-siRNA cells (>1.5-fold change in expression; P<0.05) (Fig. 2) . Of the 179 differentially expressed genes (DEGs), 38 were upregulated and 141 were downregulated in S100A4-silenced cells (data not shown in detail). Gene ontology term and KEGG pathway enrichment analyses. The molecular functions involving DEGs were identified by Gene Ontology (GO) enrichment analysis. In total, 10 GO terms were identified (Table II) . To identify well-characterized pathways that were significantly represented, the list of genes was also subjected to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Ten significantly enriched pathways were identified (Table III) , although the vast majority of the 179 DEGs could not be assigned to these signaling pathways or molecular classifications.
Validation of microarray data by qRT-PCR analysis.
The microarray data were validated by qRT-PCR analysis of RNA from the same cell samples. As shown in Fig. 3 , the expression profiles of the six genes selected from the 179 DEGs were consistent with those determined in the microarray analysis; thus, validating the accuracy of the microarray data. Among the DEGs, expression of the growth differentiation factor-15 gene (GDF15) was shown to be downregulated by 5.11-and 8.18-fold by microarray and qRT-PCR analyses, respectively. Thus, GDF15 was identified as one of the most downregulated genes in MGC803 cells following S100A4 inhibition using both these techniques.
GDF15 is an important downstream gene of S100A4. GDF15 protein expression in MGC803 cells after S100A4 inhibition was also determined by western blot analysis. S100A4-siRNA transfection induced a substantial decrease in GDF15 protein expression in MGC803 cells (Fig. 4) , further confirming that GDF15 is an important downstream gene of S100A4 and subject to positive regulation.
ChIP analysis of S100A4 binding to the GDF15 promoter.
To determine whether S100A4 binds to the GDF15 promoter in vivo, we performed chromatin immunoprecipitation (ChIP) and then analyzed the quantity of DNA fragments flanking the proximal promoter region (-113 to +61 bp) of GDF15 by qPCR. The qPCR analysis showed that the quantity of DNA fragments derived from immunoprecipitation with the anti-S100A4 antibody was almost 1.7-fold higher than that derived from immunoprecipitation with the IgG antibody (Fig. 5) . These results suggested that S100A4 might bind to the GDF15 promoter in vivo, and therefore implicates S100A4 in the regulation of GDF15 expression at the transcriptional level.
GDF15 overexpression promotes the CSC-like properties of MGC803 cells.
Compared with GV141-empty vector transfection, GV141-GDF15 transfection into MGC803 cells led to increased GDF15 expression at both the mRNA and protein levels (Fig. 6) . We then investigated the effects of GDF15 on the CSC-like properties of MGC803 cells by performing spheroid formation and soft-agar colony formation assays. More spheroids and colonies were observed in MGC803/ GV141-GDF15 cells than in MGC803/GV141-empty cells (Fig. 7) , suggesting that GDF15 overexpression promotes the CSC-like properties of MGC803 cells.
GDF15 mediates the effects of S100A4 on CSC-like properties of MGC803 cells.
We first explored the effects of S100A4 inhibition on CSC-like properties of MGC803 cells. MGC803/S100A4-siRNA cells formed fewer spheroids and colonies than MGC803/NC-siRNA cells, which suggested that S100A4 inhibition decreased the CSC-like properties of MGC803 cells (Fig. 8) . To corroborate the role of GDF15 in S100A4-regulated CSC-like properties, we carried out rescue experiments by co-transfection of S100A4-siRNA with GV141-GDF15 or GV141-empty into MGC803 cells. qRT-PCR and western blot analyses showed that compared to MGC803/ S100A4-siRNA+GV141-empty cells, MGC803/S100A4-siRNA+GV141-GDF15 cells displayed increased expression of GDF15 at 48 h after transfection. This indicated that the GV141-GDF15 vector transfection reversed the downregulation of GDF15 caused by S100A4 inhibition (Fig. 9) . Furthermore, compared with MGC803/S100A4-siRNA+GV14-empty cells, Figure 4 . The effect of S100A4 inhibition on GDF15 protein expression. GDF15 protein levels were detected by western blot analysis after S100A4 inhibition. Lanes 1 and 2, MGC803/NC-siRNA cells and MGC803/S100A4-siRNA cells, respectively, at 48 h after transfection. significantly more spheroids and colonies were formed by MGC803/S100A4-siRNA+GV14-GDF15 cells, indicating that GDF15 mediates the effects of S100A4 on the CSC-like properties of MGC803 cells (Fig. 10) .
Discussion
Many studies have shown S100A4 overexpression in various human cancers, such as hepatocellular, clear cell renal cell Figure 9 . GV141-GDF15 vector transfection reverses the downregulation of GDF15 by S100A4 inhibition. MGC803 cells were co-transfected with S100A4-siRNA and either GV141-empty vector or GV141-GDF15 vector. GDF15 expression in the co-transfected cells was analyzed by qRT-PCR (A) and western blotting (B), respectively, as described in Materials and methods. and gastric cancers, and that it is closely related to metastasis and poor patient prognosis (15) (16) (17) . Previously, our group demonstrated that reducing S100A4 expression altered cell proliferation, apoptosis, migration and anoikis in BGC823 cells in vitro, and inhibited xenograft tumor growth in vivo (8, 18, 19) . This led us to suggest that S100A4 influences key cellular processes associated with the progression of gastric cancer. To gain insight into the mechanisms underlying this process, we first performed cDNA microarray analysis of the global alterations in gene expression in MGC803 gastric cancer cells following siRNA-mediated S100A4 inhibition. Among the total genes investigated, 179 DEGs (38 upregulated and 141 downregulated) were identified in S100A4-siRNA transfected MGC803 cells compared with those transfected with NC-siRNA treated cells. In recent years, studies have shown that S100A4 inhibition leads to changes in the expression of many genes in various tumor cells. In a study of the mechanism by which S100A4 gene influences the invasiveness of prostate cancer cells using a microarray containing 96 well-characterized metastatic genes, Saleem et al (20) found that many genes, including matrix metalloproteinase 9 (MMP-9) and its tissue inhibitor (TIMP-1), were highly responsive to S100A4 gene suppression. Using metastasisrelated gene mRNA microarrays, huang et al (21) identified some significantly dysregulated genes after downregulation of S100A4, including three downregulated genes (MMP-9, MMP-10 and CDH11) and one upregulated gene (TIMP-4) in human colorectal cancer cells. Ochiya et al (22) reported that RNAi-mediated S100A4 knockdown in mouse endothelial MSS31 cells markedly suppressed in vitro capillary-like tube formation in the early stages after treatment. Furthermore, this effect was found to be associated with down-and upregulation of the expression of some pro-angiogenic (aqp1, fgf18, retn, map3k5, thy1, foxo6, hs6st1 and mmp-3) and anti-angiogenic (cdknla, thbs1 and spry4) genes. These results indicated that S100A4 influences the expression of many downstream genes in different kinds of cells. To the best of our knowledge, this study is the first to investigate the DEG profile downstream of S100A4 in gastric cancer cells. The results provide important and extensive information for the clarification of the mechanism by which S100A4 influences the progression of gastric cancer.
We undertook further bioinformatics analysis of the 179 DEGs to investigate the functional relevance of these genes. Pathway analysis showed the involvement of many of the 179 DEGs in 10 pathways, including the p53 signaling pathway, focal adhesion, ECM receptor interactions and others. GO annotation analysis revealed that DEGs were related to 10 types of molecular functions, including transferase activity, kinase activity, receptor binding and others. Nevertheless, a large number of the 179 DEGs were not associated with these pathways or molecular functions and their functions should not be ignored. In combination, our findings indicate that S100A4 participates in a variety of pathways and influences many types of molecular functions by regulating downstream gene expression in gastric cancer cells.
Growth differentiation factor-15 (GDF15), also known as MIC-1, PTGFB and PLAB (23) (24) (25) , is a divergent member of the TGF-β superfamily (26, 27) . Although normally undetectable under physiologic conditions in any tissues except the placenta (28), GDF15 becomes highly upregulated under some pathological conditions, such as cancer, myocardial infarction and inflammation (29) . GDF15 has been shown to be a marker of mortality with high serum levels being a predictor of death, particularly due to cancer (30) . Elevated circulating GDF15 levels may correlate with poor clinical outcomes in endometrial cancer and can be used as a biomarker of the endometrial cancer phenotype, including the presence of lymph node metastasis and reduced survival (31) . In addition, GDF15 exerts an antiapoptotic effect on oral squamous cell carcinoma cells in vitro (32) . Tsui et al (33) demonstrated that GDF15 overexpression induces cell proliferation, invasion, and tumorigenesis of PC-3 prostate carcinoma cells. All these results indicate that GDF15 plays important roles in many types of cancers. Furthermore, in this study, GDF15 was found to be one of the most notable DEGs, with downregulated expression after S100A4 inhibition exceeding 5-fold identified in microarray analysis and 8-fold in the qRT-PCR analysis. These results indicate that GDF15 is an important downstream gene of S100A4 and is upregulated by it; consequently, we focused on GDF15 in further research. First, we investigated the effects of S100A4 on GDF15 expression in gastric cancer cells. Previous report showed that S100A4 protein could interact with p53 protein and influence the expression of p53 target genes, such as TSP-1 and MDM2 in CSML-0 murine non-metastatic adenocarcinoma cells (34) . Furthermore, cDNA microarray analysis in this study also showed differential expression of these genes after S100A4 inhibition in gastric cancer MGC803 cells, which indicated that S100A4 may also affect the expression of p53 target genes in MGC803 cells. Recently, it has been reported that GDF15 is a direct target of p53 (35) . ChIP analysis performed in this study to explore the mechanisms by which S100A4 regulates GDF15 expression revealed that S100A4 protein binds to the proximal promoter region of GDF15, which contains the p53 binding sites as reported (36) . We speculated that S100A4 functions as a co-factor, interacting with p53 to regulate GDF15 expression at the transcriptional level in MGC803 cells. In addition, the proximal promoter region of GDF15 investigated in our ChIP analysis contains binding sites for other transcription factors such as Sp1 (37) and EGR-1 (38) . Thus, it can be speculated that S100A4 may also affect the expression of GDF15 by cooperating with Sp1, EGR-1 or other transcriptional factors. however, the underlying mechanism remains to be elucidated.
Next, we investigated the functional significance of GDF15 in gastric cancer. It has been reported that GDF15 is upregulated at the transcriptional level in tissues and cell lines of gastric cancers and GDF15 increased the invasiveness of gastric cancer cells through regulation of urokinase plasminogen activator (39, 40) . In addition, studies have shown that serum levels of GDF15 and MMP-7 have diagnostic value for gastric cancers. The combination marker formed by GDF15, MMP-7 and miR-200c is indicative of adverse evolution in gastric cancer patients (41) . however, the role of GDF15 in gastric cancer is far from clear. Recent studies show that GDF15 can enhance the tumor-initiating and self-renewal potential of multiple myeloma cells (42) . Therefore, we speculated that GDF15 might affect CSC-like properties of gastric cancer cells. To investigate this, we analyzed the CSC-like properties of MGC803 cells transfected with a GDF15 expression vector. We found that the numbers of spheroids and colonies were increased significantly after GDF15 expression vector transfection, indicating that GDF15 promotes the CSC-like properties of MGC803 cells.
Our previous findings showed that IL-1β regulates spheroid and soft-agar colony forming abilities of MGC803 cells through S100A4, suggesting that S100A4 might be involved in the regulation of CSC-like properties (unpublished data). In this study, we showed that S100A4 inhibition led to decreased spheroid and soft-agar colony forming abilities of MGC803 cells, demonstrating that S100A4 promotes the CSC-like properties of MGC803 cells.
Based on these findings, we speculated that GDF15 might influence the effects of S100A4 on the CSC-like properties in MGC803 gastric cancer cells. To test this hypothesis, we carried out rescue experiments by co-transfection of S100A4-siRNA with GV141-GDF15 or GV141-empty into MGC803 cells. The results showed that GV141-GDF15 vector transfection reversed the reduced spheroid and soft-agar colony forming abilities induced by S100A4 inhibition. These findings suggest that, as a downstream effector, GDF15 at least partly mediates S100A4 regulation of CSC-like properties in MGC803 cells.
In conclusion, we conducted the first expression profile analysis of S100A4 downstream genes in MGC803 gastric cancer cells, followed by experimental validation and functional analysis. Our results suggest that S100A4 influences the expression of many genes in gastric cancer cells. S100A4 can bind to the GDF15 promoter and may regulate its expression at the transcriptional level. We also provide experimental evidence suggesting that GDF15 promotes the CSC-like properties of MGC803 gastric cancer cells, and that S100A4 influences this effect by regulating GDF15 expression. These data provide a novel overview of the effect of S100A4 on the expression of downstream genes, and an insight into the mechanisms by which S100A4 influences the CSC-like properties of MGC803 gastric cancer cells.
